PHRX.CN Pharmadrug Inc. (CNQ) rises 50% in market hours: watch volume for follow-through

PHRX.CN stock rose 50.00% to C$0.015 during market hours on 10 Feb 2026 on above-average activity, marking it among today’s top gainers on the CNQ exchange in Canada. The intraday range ran from C$0.01 to C$0.015, with 19,428.00 shares traded versus a 50-day average of 46,944.00. Investors reacted to renewed interest in the company’s psychedelics and natural-medicines pipeline alongside existing research ties to the University of Michigan and Johns Hopkins. This note breaks down the move, fundamentals, technicals, a Meyka AI grade, and a short-term forecast to help frame risk and potential follow-through.

PHRX.CN stock: intraday price action and volume

PHRX.CN stock traded up to C$0.015 after opening at C$0.01, a C$0.005 rise and 50.00% gain on the day. The reported volume was 19,428.00, or 0.41x of the average daily volume, which suggests a price move on modest liquidity rather than a broad-based breakout. The day high matched the close at C$0.015, while the 52-week high and low remain C$0.025 and C$0.005 respectively.

PHRX.CN stock: fundamental snapshot

Pharmadrug Inc. (PHRX.CN) is a small-cap healthcare issuer with a market capitalization of C$1,623,516.00 and 108,234,380.00 shares outstanding. Key ratios show an EPS of -0.01, a trailing PE of -1.50, and a book value per share of -0.0139, indicating negative equity per share. The company reports a current ratio of 0.01 and enterprise value of C$3,107,487.00, reflecting tight liquidity and elevated balance-sheet leverage relative to operating size.

PHRX.CN stock: technicals and short-term momentum

Technicals show neutral momentum with an RSI of 45.33 and ADX of 20.55, while Bollinger bands sit at Upper 0.02, Middle 0.02, Lower 0.01. On-chain volume indicators show OBV at 1,828,236.00, and MFI reads 19.51 suggesting oversold money flow prior to the rally. Low average volume and a relVolume of 0.41 mean follow-through requires a clear increase in daily turnover.

Meyka AI rates PHRX.CN with a score out of 100 and forecast

Meyka AI rates PHRX.CN with a score out of 100: 68.08 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Meyka AI’s forecast model projects a short-term target of C$0.02 (quarterly) and a monthly baseline of C$0.01. Versus the current price C$0.015, the model implies an upside of 33.33% to the C$0.02 target. Forecasts are model-based projections and not guarantees.

PHRX.CN stock: catalysts and clinical partnerships

Pharmadrug’s pipeline and institutional agreements are the primary catalysts cited by market participants. The company lists research agreements with the University of Michigan and Johns Hopkins, and a manufacturing agreement with Southwest Research Institute, which can drive re-rating if clinical progress or regulatory clarity arrives. The firm also imports medical cannabis into Germany and the EU, a commercial revenue path that remains modest but strategic.

PHRX.CN stock: risks, liquidity and sector context

PHRX.CN operates in the Healthcare sector where group performance has been mixed and short-term volatility is high; the sector shows negative one-day movement and a longer-term cautious profile. Major risks include negative equity per share, thin liquidity, negative EPS, regulatory and clinical trial outcomes, and concentrated research-stage assets. For traders, the combination of very low market cap and low average volume raises execution and volatility risk.

Final Thoughts

PHRX.CN stock’s 50.00% intraday rise to C$0.015 on 10 Feb 2026 reflects short-term buying interest in Pharmadrug Inc.’s psychedelics and natural-medicines narrative, but the move rests on modest volume relative to the 50-day average. Our analysis points to three practical takeaways: first, fundamentals remain stretched with EPS -0.01 and trailing PE -1.50, underlining ongoing loss-making status. Second, technicals show room for follow-through if volume expands beyond the 46,944.00 average. Third, Meyka AI’s forecast model projects a near-term target of C$0.02, implying 33.33% upside from the current price, while a conservative downside reference sits at C$0.01. Investors should weigh the company’s research partnerships and small revenue base against liquidity and regulatory risks. For deeper tracking, see the Pharmadrug company site and our real-time coverage on Meyka AI’s platform for updates and model revisions. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.